Search Results

Press Releases

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

December 12, 2024

·

19 min read

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

October 2, 2024

·

7 min read

BioForest

Kineta to Present at Upcoming Investor Conferences

Kineta, Inc. announced today that the Company will be attending and presenting at the following upcoming investors conferences.

February 14, 2024

·

1 min read

BioForest

Kineta Announces Restructuring and Exploration of Strategic Alternatives

Kineta, Inc. announced today that it has completed a review of its business, including the status of its programs, resources and capabilities.

February 29, 2024

·

6 min read

Press Releases

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

November 8, 2024

·

10 min read

Business

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

October 4, 2024

·

6 min read

Press Releases

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

October 9, 2024

·

7 min read

Business

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

March 21, 2024

·

11 min read

Business

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies in oncology that address cancer immune resistance, announced today financial results for the three months ended March 31, 2024 and provided a corporate update.

May 15, 2024

·

10 min read

BioForest

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024.

February 7, 2024

·

5 min read